oxycodone HCl

This page contains recent news articles, when available, and an overview of oxycodone HCl but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Overview:

oxycodone HCl (when available)

Pharmacology and use:
Oxycodone, a semisynthetic opiate agonist derived from the opioid alkaloid, thebaine, is similar to other phenanthrene derivatives such as hydrocodone and morphine. Oxycodone is available in combination with aspirin or acetaminophen to control pain and restless leg and Tourette syndromes. For the treatment of diarrhoea, pulmonary oedema; For the relief of moderate to moderately severe pain

Mechanism Of Action:
Oxycodone acts as a weak agonist at OP1, OP2, and OP3 opiate receptors within the central nervous system (CNS). Oxycodone primarily affects OP3 receptors, which are coupled with G-protein receptors and function as modulators, both positive and negative, of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine, and noradrenaline is inhibited. Opioids such as Oxycodone also inhibit the release of vasopressin, somatostatin, insulin, and glucagon. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.

News Articles on Oxycodone

King Pharmaceuticals Reports First-Quarter 2008 Financial Results  -  May 8, 2008
ACUROX™ Tablets, an investigational drug, is an orally administered immediate-release tablet containing oxycodone HCl as an active analgesic ingredient, Business Wire (press release),

King Pharmaceuticals Exercises Option to License Third Opioid ...  -  May 27, 2008
The Agreement provides King with an exclusive license to ACUROX(tm) (oxycodone HCl, niacin, and functional inactive ingredients) tablets and another Primenewswire (press release),

Tapentadol Effective for Chronic Pain Due to Knee Osteoarthritis ...  -  Apr 16, 2008
..."Also, tapentadol ER 100 mg was associated with an efficacy outcome similar to oxycodone HCl CR 20 mg." Osteoarthritis is the most common form of arthritis. DG News

Watson Pharma swings to profit  -  Feb 20, 2008
Generic product sales for the fourth quarter fell to $343.7 million from $412.8 million, primarily for the loss of revenue from oxycodone HCl Forbes,

Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 ...  -  Feb 20, 2008
Generic product sales for the fourth quarter of 2007 decreased $69.0 million to $343.7 million, primarily related to the loss of revenue from oxycodone HCl PharmaLive.com (press release),

King Pharmaceuticals Reports Year-End and Fourth-Quarter 2007 ...  -  Feb 28, 2008
These include REMOXY(TM) (long-acting oral oxycodone) and ACUROX(TM) Tablets (oxycodone HCl, niacin, and a unique combination of other ingredients), Centre Daily Times,

OTCPicks.com Daily Market Movers Digest Midday Report  -  Feb 1, 2008
...the Aversion Technology with oxycodone HCl as the active analgesic ingredient in an immediate release tablet intended for oral administration. TransWorldNews (press release),

King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to ...  -  Oct 31, 2007
ACUROX(TM) (formerly oxyadf) is an orally administered immediate release tablet containing oxycodone hcl as an active analgesic ingredient, CNNMoney.com

King signs agreement with Acura to develop pain drugs  -  Nov 2, 2007
By Staff Writer The companies have initially targeted four immediate release opioid analgesic products, including Acurox tablets (oxycodone hcl, niacin, Pharmaceutical Business Review

Watson Pharmaceuticals Reports Third Quarter 2007 Results  -  Nov 6, 2007
Generic product sales for the third quarter of 2007 decreased $21.4 million to $326.2 million, primarily related to the loss of revenue from oxycodone hcl CNNMoney.com

Centrally Acting Analgesic Tapentadol - Latest Phase II Data for ...  -  Oct 1, 2007
Patients received an oral dose of either tapentadol IR 50 mg, tapentadol IR 100 mg, oxycodone HCl IR 10 mg, or placebo every 4 to 6 hours over three days. Earthtimes.org

Acura Secures Funding for OxyADF Trial  -  Aug 21, 2007
...double-blind, placebo-controlled, multicenter, repeat-dose study of the safety and efficacy of OxyADF Tablets (oxycodone HCl and niacin). FDA news (subscription),

Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal ...  -  Aug 20, 2007
...the pivotal phase 3 trial for OxyADF (oxycodone HCl and niacin) Tablets, its lead product candidate utilizing Aversion(R) Technology. CNNMoney.com

[an error occurred while processing this directive] [an error occurred while processing this directive] [an error occurred while processing this directive] [an error occurred while processing this directive] [an error occurred while processing this directive] [an error occurred while processing this directive] [an error occurred while processing this directive] [an error occurred while processing this directive] [an error occurred while processing this directive] [an error occurred while processing this directive] [an error occurred while processing this directive] [an error occurred while processing this directive] [an error occurred while processing this directive] [an error occurred while processing this directive] Brand Names/Synonyms:
oxycodone HCl is also known by the following brand names and/or synonymsCodeinone, Dihydrohydroxy-; Combunox; Dea No. 9143; Dihydrohydroxycodeinone; Dihydrohydroxycondeinone; Dihydrone; Dihydroxycodeinone; Dinarkon; Diphydrone; ENDOCET; ENDODAN; Endone; Eubine; Eubine [France]; Eucodal; Eucodalum; Eukodal; Eutagen; HSDB 3142; Ossicodone [Dcit]; Oxanest; Oxicodona [Inn-Spanish]; Oxicon; Oxicone; Oxikon; Oxycet; Oxycodeinone; Oxycodon; Oxycodone; Oxycodone Hcl; Oxycodone Hydrochloride; Oxycodone [Usan:Ban:Inn]; Oxycodonum [Inn-Latin]; Oxycon; Oxycontin; PERCOCET; Pancodine; Percobarb; Percocet; Percodan; Roxicet; Roxicodone; Roxilox; Supendol [Canada]; Tecodin; Tekodin; Thecodine; Thekodin; Tylox

Drug Category:
oxycodone HCl is categorized under the following by the FDA: Narcotics; Antitussives; Analgesics, Opioid; Opiate Agonists; ATC:N02AA05

Dosage Forms:
Tablet; Suppository

Absorption:
well absorbed from OxyContin� tablets with an oral bioavailability of 60% to 87%

Interactions:
Interactions for Oxycodone:

The CNS depressant effects of oxycodone hydrochloride may be additive with that of other CNS depressants..

Chemical IUPAC Name:
4, 5-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one

:

Web health.mongabay.com

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com lead to other sites. health.mongabay.com does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com responsible for dead or misdirected links.